XRAY — DENTSPLY SIRONA Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Instruments & Supplies·USA

Latest market price

9.54

+0.16+1.71%

Overview Short InterestFilings

XRAYQT44DENTSPLY SIRONA Inc.·NASDAQ

Overview Short InterestFilings

9.54+1.71%

News

Up 1.7% — DENTSPLY SIRONA (NASDAQ:XRAY) Reaches New 1-Year Low – Time to Sell? (defenseworld.net).

Medium confidence

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

LMAT-0.76%$78.87 BLFS-0.43%$36.69 AZTA-1.16%$33.24 KMTS+0.33%$24.43 ATRC-1.73%$58.10 STAA-1.98%$20.82 PLSE+6.44%$53.87 NVST-1.44%$23.35

Snapshot

Index	-	P/E	-	EPS (ttm)	-2.74	Insider Own	3.16%	Shs Outstand	200.33M	Perf Week	-8.80%

Market Cap	1.91B	Forward P/E	6.32	EPS next Y	1.51	Insider Trans	0.97%	Shs Float	199.22M	Perf Month	-13.51%

Enterprise Value	3.98B	PEG	-	EPS next Q	0.30	Inst Own	-	Short Float	11.09%	Perf Quarter	-7.65%

Income	-546.00M	P/S	0.52	EPS this Y	155.80%	Inst Trans	-	Short Ratio	4.31	Perf Half Y	-15.28%

Sales	3.64B	P/B	1.41	EPS next Y	-1.28%	ROA	-10.49%	Short Interest	22.09M	Perf YTD	-16.54%

Book/sh	6.74	P/C	8.00	EPS next 5Y	2.29%	ROE	-39.81%	52W High	14.76 -35.37%	Perf Year	-28.97%

Cash/sh	1.19	P/FCF	14.65	EPS past 3/5Y	-	ROIC	10.03%	52W Low	9.36 1.92%	Perf 3Y	-73.34%

Dividend Est.	0.64 (6.71%)	EV/EBITDA	23.16	Sales past 3/5Y	-2.10% 1.96%	Gross Margin	49.52%	Volatility	4.71% 3.82%	Perf 5Y	-84.33%

Dividend TTM	0.32 (3.35%)	EV/Sales	1.09	EPS Y/Y TTM	38.84%	Oper. Margin	11.69%	ATR (14)	0.47	Perf 10Y	-84.19%

Dividend Ex-Date	Dec 26, 2025	Quick Ratio	1.07	Sales Y/Y TTM	-3.95%	Profit Margin	-14.99%	RSI (14)	31.55	Recom	2.66

Dividend Gr. 3/5Y	8.58% 9.86%	Current Ratio	1.63	EPS Q/Q	0.00%	SMA20	-10.77%	Beta	0.85	Target Price	13.40

Payout	-17.58%	Debt/Eq	1.84	Sales Q/Q	-4.06%	SMA50	-19.99%	Rel Volume	1.65	Prev Close	9.38

Employees	14,000	LT Debt/Eq	1.57	Earnings	Nov 05	SMA200	-18.55%	Avg Volume	5.11M	Price	9.54

IPO Date	Aug 12, 1987	Option/Short	Yes / Yes	EPS/Sales Surpr.	49.44% 0.91%	Net Debt/EBITDA	12.05	Volume	8,453,163	Change	1.71%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-17-26	Reiterated	BMO Capital	Market Perform	$13 → $10
Aug-24-26	Reiterated	Barclays	Underweight	$9.00 → $11
Aug-10-26	Reiterated	Barrington	Outperform	$17 → $15
Aug-07-26	Reiterated	BMO Capital		$12 → $13
Jul-29-26	Reiterated	Piper Sandler	Neutral	$32 → $14
Jul-08-26	Initiated	BMO Capital	Market Perform	$12
Jun-04-26	Reiterated	Barclays	Underweight	$12 → $9.00
May-07-26	Reiterated	UBS	Buy	$16 → $17
Feb-19-26	Upgrade	B of A Securities	Neutral → Buy
Feb-03-26	Reiterated	UBS	Buy	$23 → $16

Latest News· Times ET

Sep-18-26

Sep-18-2612:10AM

DENTSPLY SIRONA (NASDAQ:XRAY) Reaches New 1-Year Low – Time to Sell?defenseworld.net

Sep-17-26

Sep-17-2611:13PM

Engineers Gate Manager LP Boosts Stake in DENTSPLY SIRONA Inc. $XRAYdefenseworld.net

08:26AM

Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Nowzacks.com

Sep-11-26

Sep-11-2601:15PM

3 Russell 2000 Stocks We Steer Clear OfYahoo

Sep-08-26

Sep-08-2609:15AM

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressurezacks.com

Sep-07-26

Sep-07-2611:32AM

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com

Sep-03-26

Sep-03-2604:15PM

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare ConferenceYahoo

Sep-02-26

Sep-02-2605:00AM

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunitiesyoutube.com

Aug-24-26

Aug-24-2606:17AM

Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11Benzinga

Aug-20-26

Aug-20-2607:11AM

3 Unprofitable Stocks with Open QuestionsYahoo

Aug-19-26

Aug-19-2604:30AM

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinenceprnewswire.com

Aug-14-26

Aug-14-2612:45AM

Dentsply Sirona (XRAY) Q2 2026 Earnings Call TranscriptYahoo

Aug-11-26

Aug-11-2612:13AM

Why Dentsply Sirona (XRAY) Stock Is Trading Lower TodayYahoo

Aug-07-26

Aug-07-2611:32PM

Empowered Funds LLC Grows Stake in DENTSPLY SIRONA Inc. $XRAYdefenseworld.net

01:06PM

DENTSPLY SIRONA Q2 Earnings Call Highlightsmarketbeat.com

Company

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	3,643	3,680	3,793	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	1,839	1,840	1,835	—	—	—	—	—	—
Gross Profit	1,804	1,840	1,958	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	1,458	1,438	1,605	—	—	—	—	—	—
Research and Development	166	150	165	—	—	—	—	—	—
Other Operating Expense	-246	0	1,067	—	—	—	—	—	—
Operating Income	426	252	-879	—	—	—	—	—	—
Interest Expense	91	88	69	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-682	-650	12	—	—	—	—	—	—
Net Income Before Taxes	-347	-486	-936	—	—	—	—	—	—
Income Taxes	200	112	-26	—	—	—	—	—	—
Consolidated Net Income	-546	-598	-910	—	—	—	—	—	—
Net Income From Continuing Operations	-547	-598	-910	—	—	—	—	—	—
Net Income	-546	-598	-910	—	—	—	—	—	—
EPS (Recurring)	-2.74	-3.00	-4.48	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.74	-3.00	-4.48	—	—	—	—	—	—
EPS (Diluted)	-2.74	-3.00	-4.48	—	—	—	—	—	—
EBITDA	172	-46	-518	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	0.52	0.62	1.02	—	—	—	—	—	—
Gross Margin	49.52	50.00	51.62	—	—	—	—	—	—
Operating Margin	11.69	6.85	-23.17	—	—	—	—	—	—
Net Margin	-14.99	-16.25	-23.99	—	—	—	—	—	—
Shares Outstanding	200	199	203	—	—	—	—	—	—
Market Capitalization	1,908	2,275	3,853	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAZELSKY JONATHAN JAY	Director	Jun 12 '26	Buy	10.14	10,000	101,400	61,669	Jun 18
HOSEIN CLYDE	Director	Jun 15 '26	Buy	9.98	6,500	64,902	70,575	Jun 16
Gladden Brian T	Director	Jun 15 '26	Buy	10.02	9,985	100,000	61,849	Jun 15
MCKEON BRIAN P	Director	Jun 12 '26	Buy	10.12	10,000	101,200	10,000	Jun 15
Barber Michael J	Director	Jun 11 '26	Buy	9.88	15,175	150,005	55,943	Jun 15
HOLDEN BETSY D	Director	Jun 11 '26	Buy	9.88	10,086	99,692	87,528	Jun 15
LUCIER GREGORY T	Director	Mar 09 '26	Buy	12.45	15,000	186,675	65,000	Mar 09
Forbes James D	Director	Mar 09 '26	Buy	12.48	5,000	62,400	10,000	Mar 09
LUCIER GREGORY T	Director	Mar 03 '26	Buy	14.03	22,445	314,858	50,000	Mar 03
Forbes James D	Director	Mar 03 '26	Buy	13.47	5,000	67,345	5,000	Mar 03
LUCIER GREGORY T	Director	Mar 02 '26	Buy	14.24	27,555	392,521	27,555	Mar 03
LUCIER GREGORY T	Director	Dec 08 '25	Sale	11.14	82,200	915,708	0	Dec 10
VARON LESLIE F	Director	Nov 24 '25	Buy	10.71	9,337	99,999	57,343	Nov 25
LUCIER GREGORY T	Director	Mar 03 '25	Buy	16.51	15,142	249,994	81,971	Mar 03
LUCIER GREGORY T	Director	Nov 18 '24	Buy	18.37	10,000	183,700	71,730	Jan 29

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.